Torres-Carrillo Norma, Torres-Carrillo Nora Magdalena, Martínez-Bonilla Gloria Esther, Vázquez-Del Mercado Mónica, Palafox-Sánchez Claudia Azucena, Oregón-Romero Edith, Bernard-Medina Ana Guilaisne, Rangel-Villalobos Héctor, Muñoz-Valle José Francisco
Departamento de Biología Molecular y Genómica, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Clin Exp Med. 2009 Sep;9(3):223-8. doi: 10.1007/s10238-009-0038-0. Epub 2009 Feb 24.
Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of plasmin production. Plasmin can directly or indirectly to degrade cartilage and bone matrix. The PAI-1 HindIII polymorphism has been associated with high PAI-1 plasma levels in myocardial infarction patients and control populations. Furthermore, it has been associated with the angiographic extent of coronary artery disease, but their involvement in other diseases is still uncertain. Here, we assessed the relationship between PAI-1 HindIII polymorphism and PAI-1 plasma levels in rheumatoid arthritis (RA). One hundred and twenty-five RA patients and 132 control subjects (CS) were included. Genotypes were identified by the polymerase chain reaction-restriction fragment length polymorphism technique and PAI-1 plasma levels were quantified using an ELISA kit. Not significant differences in genotype and allele frequencies between both studied groups were observed (P > 0.05). RA patients showed lower PAI-1 plasma levels (18.92 +/- 12.94 ng/ml) than CS (23.68 +/- 23.38 ng/ml), without significant difference (P = 0.299). However, in RA patients the C/G genotype carriers showed higher PAI-1 plasma levels (23.00 +/- 13.81 ng/ml) with respect to C/C (16.77 +/- 11.97 ng/ml) and G/G (10.47 +/- 7.07 ng/ml) genotype carriers (P = 0.036). The PAI-1 HindIII polymorphism was not associated with RA susceptibility. However, the C/G genotype is associated with high PAI-1 plasma levels in RA patients.
1型纤溶酶原激活物抑制剂（PAI - 1）是纤溶酶产生的抑制剂。纤溶酶可直接或间接降解软骨和骨基质。PAI - 1 HindIII多态性与心肌梗死患者及对照人群的血浆PAI - 1高水平有关。此外，它还与冠状动脉疾病的血管造影范围有关，但其在其他疾病中的作用仍不确定。在此，我们评估了类风湿关节炎（RA）患者中PAI - 1 HindIII多态性与血浆PAI - 1水平之间的关系。纳入了125例RA患者和132例对照者（CS）。通过聚合酶链反应 - 限制性片段长度多态性技术鉴定基因型，并使用酶联免疫吸附测定试剂盒定量血浆PAI - 1水平。在两个研究组之间未观察到基因型和等位基因频率的显著差异（P>0.05）。RA患者的血浆PAI - 1水平（18.92±12.94 ng/ml）低于CS（23.68±23.38 ng/ml），差异无统计学意义（P = 0.299）。然而，在RA患者中，C/G基因型携带者的血浆PAI - 1水平（23.00±13.81 ng/ml）高于C/C（16.77±11.9
